Abstract
Acute myeloid leukemia (AML) is a heterogeneous malignant hematological neoplasm caused by the accumulation of mutations and molecular alterations in hematopoietic stem cells and corresponds to the highest number of annual deaths from leukemias. The treatment of patients with AML has remained substantially unchanged for over 30 years. Recently, the AML treatment paradigm has been overcome…